Press Release

Tactical Therapeutics on WSJ

Special Biotechnology Report
24 June 2009,
Washington Post.

Click here to download the pdf

9 May 2006  ,
Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006

View more
Financing Sought

Private Funding by Angel Investors



Angiogenesis inhibitors are expected to be used in the therapies of several different cancers-colon, breast, prostate, ovarian, head & neck/esophageal, pancreatic and lung among others.  CTO is a small molecule and it can be given orally. In addition, CTO is a synthetic oral inhibitor of calcium influx and has demonstrated anti-invasive and anti-proliferative properties. Most importantly, it will be cost effective in comparison to comparable biological angiogenesis inhibitors.


In Phase I CTO demonstrated activity in refractory tumors which were pretreated with targeted and non-targeted agents. Based on those results, CTO is being developed in several Phase II trials, ex. malignant ghomas and glioblastoma, ovarian cancer, non-small cell lung cancer, head, neck and metastatic colorectal cancer.


Copyright @ 2006, Tactical Therapeutics, Inc